Full Press Release Details
Announces Appointment of Medical Device Industry Veteran
Gago as Chief Commercial Officer
MA - October 26, 2016 - InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) ("InspireMD" or the "Company"),
a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the
appointment of Agustin Gago as the Company's Executive Vice President and Chief Commercial Officer. In this role, Mr. Gago
will be responsible for developing and implementing InspireMD's global sales, distribution and marketing strategy for the
Company's CGuard EPS, MGuard Prime EPS , as well as all future pipeline products.
am excited to welcome Agustin to the InspireMD team", said James Barry, PhD, Chief Executive Officer of InspireMD. "Agustin
brings a wealth of experience in building and leading global commercial organizations. He will be an invaluable asset to InspireMD
as we focus on expanding company sales in the global market place. His successful track record and comprehensive expertise in
cardiology, oncology and diagnostic imaging will strengthen our sales and marketing organization. Agustin will be a key addition
to our management team as we focus on revenue growth and broadening our product pipeline."
Gago has over 25 years of experience in building profitable international commercial, sales and marketing organizations. Before
joining InspireMD, he served as a Principal at Dash International, LLC, a consulting firm he founded in 2013, advising CEOs and
Boards of Directors of major medical device companies on business strategy. Prior to this, he served as Chief Commercial Officer
at Delcath Systems, Inc., an interventional oncology company, creating its direct and contract sales forces as well as a distributor
infrastructure serving Europe, Asia and South America. Before his time at Delcath Systems, Mr. Gago was Vice President of International
Oncology Surgery Sales at AngioDynamics, Inc., a provider of minimally invasive medical devices for cardiology vascular disease
and oncology. There, he was also responsible for the launch of their interventional cardiology product line. Mr. Gago also worked
for 10 years in various leadership roles at E-Z-EM, Inc., a global manufacturer of medical devices and contrast agents for gastrointestinal
imaging, eventually being appointed Vice President of Global GI Business and Vice President of International Operations. Mr. Gago
is fluent in several foreign languages including Spanish and Portuguese.
am pleased to be joining InspireMD, a company whose cutting-edge technology and products have the potential to truly be a game
changer for patients with carotid artery, neurovascular and coronary artery disease," said Mr. Gago. "I look forward
to working with my new team to advance InspireMD's position and products within the Global market place."
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuardTM), neurovascular, and peripheral artery
procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants are quoted
on the NYSE MKT under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.